GSK PLC GSK
News
Vocabria + Rekambys associated with greater adherence versus daily oral therapy in a US real-world study, as ViiV Healthcare presents broader long-acting portfolio and pipeline data at HIV Glasgow
ViiV Healthcare Commits $100 Million to Build More Resilient Local HIV Care Networks Across the United States
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
GSK Shares Slide After Vaccine Sales Disappoint
GSK Sales Get Boost From Specialty Medicines
Five years of U.S. real-world evidence reinforce the durable effectiveness and long-term persistence of ViiV Healthcare’s Cabenuva
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)
Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
GSK Says FDA Approved Jemperli For Certain Types of Rectal Cancer
GSK Says Lung-Cancer Drug Shows Benefits in Global Trial
Flu season is already here. Here's what to know about this year's flu shots.
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
European Pharma Leaders Push for National Reforms to Boost Investment
ViiV Healthcare Partners with Prevention Access Campaign (PAC) to Celebrate 10 Years of U=U and Look to The Future
Is the shingles vaccine the secret to living longer and delaying dementia? Here's what the science says.
Empowering Communities: ViiV Healthcare Awards $33 Million in Grants to Advance HIV Response in the U.S.
GSK Says New Lung-Cancer Drug Shows Benefits at Earlier Stage of Treatment
Hutchmed Enters Licensing Agreement With GSK for Cancer Drug



